Ras family of small gtpases in crc: New perspectives for overcoming drug resistance
EntityUAM. Departamento de Medicina
10.3390/cancers13153757Cancers 13.15 (2021): 3757
Funded byThis research was funded by Spanish Health Institute Carlos III (ISCIII), grant number PI19/01231. A.R-V was funded by a contract PFIS from Spanish Health Institute Carlos III (ISCIII) (FI20/00213) associated with the project PI19/01231.
ProjectGobierno de España. PI19/01231; Gobierno de España. FI20/00213; Gobierno de España. PI19/01231
SubjectsColorectal cancer; Drug resistance; EGFR targeted therapies; Ras-GTPases; Medicina
Rights© 2021 by the authors
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Colorectal cancer remains among the cancers with the highest incidence, prevalence, and mortality worldwide. Although the development of targeted therapies against the EGFR and VEGFR membrane receptors has considerably improved survival in these patients, the appearance of resistance means that their success is still limited. Overactivation of several members of the Ras-GTPase family is one of the main actors in both tumour progression and the lack of response to cytotoxic and targeted therapies. This fact has led many resources to be devoted over the last dec-ades to the development of targeted therapies against these proteins. However, they have not been as successful as expected in their move to the clinic so far. In this review, we will analyse the role of these Ras-GTPases in the emergence and development of colorectal cancer and their relationship with resistance to targeted therapies, as well as the status and new advances in the design of targeted therapies against these proteins and their possible clinical implications.
Google Scholar:Rio-Vilariño, Anxo - Del Puerto-Nevado, Laura - García-Foncillas López, Jesús Miguel - Cebrián, Arancha
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept Martínez-Useros, Javier; Georgiev-Hristov, Tihomir; Fernández-Aceñero, María Jesús; Borrero-Palacios, Aurea; Indacochea, Alberto; Guerrero, Santiago; Li, Weiyao; Cebrián, Arancha; Gómez del Pulgar, Teresa; Puime-Otin, Alberto; Puerto-Nevado, Laura del; Rodríguez-Remírez, María; Pérez, Nuria; Celdrán, Angel; Gebauer, Fátima; García-Foncillas López, Jesús Miguel
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer Borrero-Palacios, A.; Cebrián, A.; Gómez del Pulgar, M. T.; García-Carbonero, R.; García, P.; Aranda, E.; Elez, E.; López-López, R.; Cervantes, A.; Valladares, M.; Nadal, C.; Viéitez, J. M.; Guillén-Ponce, C.; Rodríguez, J.; Hernández, I.; García, J. L.; Vega-Bravo, R.; Puime-Otin, A.; Martínez-Useros, J.; Del Puerto-Nevado, L.; Rincón, R.; Rodríguez-Remírez, M.; Rojo, F.; García-Foncillas López, Jesús Miguel